Cisplatin + Methotrexate combination

The cisplatin + methotrexate combination is a chemotherapy regimen used primarily for treating urothelial carcinoma, including bladder cancer. This combination is often part of larger regimens such as M-VAC (Methotrexate, Vinblastine, Doxorubicin, and Cisplatin) or other variations. ## Mechanism of Action The combination works through complementary mechanisms: **Cisplatin** functions as an alkylating agent that cross-links DNA strands, preventing DNA replication and transcription. It works by: 1. Attaching alkyl groups to DNA bases, causing DNA fragmentation 2. Forming cross-links between DNA strands 3. Inducing nucleotide mispairing that leads to mutations[4] **Methotrexate** is an antimetabolite that inhibits dihydrofolate reductase, preventing the formation of tetrahydrofolate which is necessary for DNA synthesis. This blocks cell division, particularly affecting rapidly dividing cancer cells. Studies have shown that the combination of cisplatin and methotrexate exhibits moderate synergism, with the synergistic effect varying depending on dosage levels[3]. ## Clinical Applications The cisplatin + methotrexate combination is primarily used for: - Advanced or metastatic urothelial carcinoma (bladder cancer) - Often incorporated into multi-drug regimens like M-VAC In clinical studies, this combination has shown efficacy as both first-line and second-line treatment for patients with advanced urothelial carcinoma[1][5]. ## Dosing Regimens Various dosing schedules have been studied, including: - In the M-VAC regimen: methotrexate 30 mg/m² on days 1, 15, and 22; cisplatin 70 mg/m² on day 2; with cycles repeated every 28 days[1] - Other regimens combine cisplatin (30 mg/m² on days 1-3) with methotrexate (30 mg/m² on day 1)[5] ## Toxicity Profile The main adverse effects associated with this combination include: - Hematological toxicity: neutropenia, thrombocytopenia, and anemia - Renal impairment (though some studies report low incidence) - Mucositis - Nausea and vomiting The severity of these effects can be managed with appropriate supportive care, including granulocyte colony-stimulating factor in some regimens[5]. ## Efficacy When used as part of combination regimens, cisplatin + methotrexate has demonstrated response rates of approximately 30-62.5% in patients with metastatic urothelial carcinoma[1][5]. The median survival in some studies was reported as 13 months[5]. The combination has shown activity in both previously treated and untreated patients, though response rates may vary depending on prior treatment history[1].

Other names

Cisplatin + Methotrexate